UTHR — United Therapeutics Share News
0.000.00%
Last trade - 00:00- $25.46bn
- $22.80bn
- $3.18bn
Brief: United Therapeutics Q2 Revenue USD 714.9 Million Vs. IBES Estimate USD 691.9 Million
U.S. RESEARCH ROUNDUP-Corecivic, Eli Lilly, Wd-40
Brief: United Therapeutics Corporation Announces Full Enrollment Of The Teton 2 Study Of Inhaled Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
Tempus AI stretches rally as co and SoftBank launch AI healthcare JV
SoftBank-backed Tempus AI sinks to new post-IPO lows
U.S. RESEARCH ROUNDUP- Chemed, PTC Therapeutics, Regeneron Pharmaceuticals
United Therapeutics Corp reports results for the quarter ended in March - Earnings Summary
Brief: United Therapeutics Q1 Revenue USD 677.7 Million Vs. IBES Estimate USD 624 Million
United Therapeutics Corp expected to post earnings of $5.65 a share - Earnings Preview
Liquidia falls as rival Merck's therapy for lung condition gets FDA approval
U.S. RESEARCH ROUNDUP-Acuity Brands, CSG Systems International, Nuvation Bio
Brief: United Therapeutics Corporation Announces $1 Bln Accelerated Share Repurchase Program
U.S. RESEARCH ROUNDUP-CommScope Holding Company, Dutch Bros, Hess Corp
Brief: United Therapeutics Says Co Filed Motion In US District Court For Preliminary Injunction In Patent Litigation With Liquidia Technologies
United Therapeutics Corp reports results for the quarter ended in December - Earnings Summary
United Therapeutics files litigation with FDA over rival Liquidia's drug application (updated)
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application
Brief: United Therapeutics Commences Litigation With US Food And Drug Administration
Brief: United Therapeutics Q4 Revenue USD 614.7 Million Vs. IBES Estimate USD 575.9 Million